Synthesis, Absolute Configuration, Stereoselectivity, and Receptor Selectivity of $(\alpha R,\beta S)$ - α,β -Dimethylhistamine,[†] a Novel Highly Potent Histamine H₃ Receptor **Agonist[‡]**

Ralph Lipp,[‡] Jean-Michel Arrang,[#] Monique Garbarg,[#] Peter Luger,[⊥] Jean-Charles Schwartz,[#] and Walter Schunack^{*,§}

Institute of Pharmacy and Institute of Crystallography, Freie Universität Berlin, D-1000 Berlin 33, Germany, and Unité de Neurobiologie, Centre Paul Broca de l'INSERM, F-75014 Paris, France

Received May 18, 1992

Depending on the selected synthetic pathway, structural variations of the neurotransmitter histamine led to mixtures of α,β -dimethylhistamines as well as to the corresponding pure optical isomers. One of these isomers, namely $(\alpha R,\beta S)$ - α,β -dimethylhistamine, proved to be a highly potent H₃ receptor agonist with exceptional receptor selectivity. The absolute configuration of the compound was determined by X-ray structure analysis of its dihydrobromide using the anomalous dispersion of bromine. The optical purity of both enantiomers of $erythro-\alpha,\beta$ -dimethylhistamine was checked by 'H NMR investigations after acylation of the amines with (R)-2-methoxy-2-phenylacetyl chloride. As expected H_3 receptors distinguish in a very strong way between the title compound and its $\alpha S, \beta R$ -configured enantiomer. The agonistic potency of the latter is 2 orders of magnitude lower than the potency of $(\alpha R, \beta S) - \alpha, \beta$ -dimethylhistamine.

The existence of a third histamine receptor was reported for the first time in 1983.¹⁻⁴ It proved to be pharmacologically distinct from the H_1 and H_2 receptors previously described.⁵ Being presynaptically located on histaminergic neurons it modulates the synthesis of histamine as well as its release into the synaptical cleft. Thus, activation of the H_3 receptor by agonists leads to a decrease of the concentration of the neurotransmitter histamine in the synaptical cleft.6

Although the number of H_3 receptors is higher in the central nervous system (CNS),⁷ H₃ receptors are located on several peripheral tissues as well.⁸⁻¹⁰ Meanwhile the existence of H₃ receptors in the human brain has also been

¹ Institute of Crystallography, Freie Universität Berlin.

(1) Arrang, J.-M.; Garbarg, M.; Schwartz, J.-C. Auto-Inhibition of Brain Histamine Release Mediated by a Novel Class (H3) of Histamine Receptor. Nature (London) 1983, 302, 832-837.

(2) Arrang, J.-M.; Garbarg, M.; Schwartz, J.-C. Auto-regulation of Histamine Release in Brain by Pre-synaptic H₃-Receptors. Neuroscience 1985, 15, 553-562

(3) Arrang, J.-M.; Garbarg, M.; Schwartz, J.-C. Auto-inhibition of Histamine Synthesis Mediated by Pre-synaptic H₃-Receptors. Neuroscience 1987, 23, 149-157.

(4) Ishikawa, S.; Sperelakis, N. A Novel Class (H₃) of Histamine Receptors on Perivascular Nerve Terminals. Nature (London) 1987, 327, 158-160.

(5) Schwartz, J.-C.; Arrang, J.-M.; Garbarg, M.; Pollard H. A. Third Histamine Receptor Subtype, Localization and Functions of the H₃-Receptor. Agents Actions 1990, 30, 13-23.

(6) Schwartz, J.-C.; Arrang, J.-M.; Garbarg, M.; Korner, M. Properties and Roles of the Three Subclasses of Histamine Receptors in Brain. J. Exp. Biol. 1986, 124, 203-224.

(7) Arrang, J.-M.; Garbarg, M.; Lancelot, J.-C.; Lecomte J.-M.; Pollard, H.; Robba, M.; Schunack, W.; Schwartz, J.-C. Highly Potent and Selective Ligands for Histamine H₃-Receptors. Nature (London) 1987, 327, 117-123

(8) Ea-Kim, L.; Oudart, N. A. Highly Potent and Selective H₃ Agonist Relaxes Rabbit Middle Cerebral Artery, In Vitro. Eur. J. Pharmacol. 1988, 150, 393-396.

 (9) Ichinose, M.; Stretton, C. D.; Schwartz, J.-C.; Barnes, P. J. Histamine
H₃ Receptors Inhibit Cholinergic Neurotransmission in Guinea Pig Airways. Br. J. Pharmacol. 1989, 97, 13-15.

established¹¹ and with (αR) - α -methylhistamine⁷ (Figure 1) the first H_3 agonist has been introduced into clinical trials with human volunteers.¹² The potential therapeutic value of the drug regarding treatment of diseases in the CNS as well as in the respiratory and the gastrointestinal field is currently under investigation within these studies.

Several synthetic attempts have been carried out in search of selective and potent ligands for the H₃ receptor. These trials in the area of H_3 antagonists have led to a number of compounds with good pharmacological in vitro activity,¹³⁻¹⁸ but so far only a few selective agonists have been identified.⁵ Especially (αR) - α -methylhistamine proved to be highly potent at H₃ receptors while displaying

(12) Arrang, J.-M.; Garbarg, M.; Schwartz, J.-C.; Lipp, R.; Stark, H.; Schunack, W.; Lecomte, J. M. The Histamine H₃-Receptor: Roles and Clinical Implications Studied with Agonists. In New perspectives in histamine research; Timmerman, H.; van der Goot, H., Eds.; Birkhäuser

Verlag: Basel, 1991; pp 55-67. (13) Arrang, J.-M.; Garbarg, M.; Lancelot, J.-C.; Lecomte, J.-M.; Robba, M.-F.; Schwartz, J.-C. Preparation and Therapeutic Application of (Imidazol-4-yl)piperidines. Eur. Pat. Appl. 0 197 840, 1986 (Institut national de la santé et de la recherche médicinale, Université de Caen, Société Civile Bioprojet).

(14) Van der Werf, J. F.; Bijloo, G. J.; Van der Vliet, A.; Bast, A. Timmerman, H. H₃ Receptor Assay in Electrically-Stimulated Superfused Slices of Ratbrain Cortex; Effects of Na-Alkylated Histamines and Impromidine Analogues. Agents Actions 1987, 20, 239–243. (15) Van der Werf, J. F.; Bijloo, G. J.; Van der Vliet, A.; Timmermann,

H. HA Autoreceptor Assay with Superfused Slices of Rat Brain Cortex

H. HA Autoreceptor Assay with Superfused Sides of Rat Brain Cortex and Electrical Stimulation. Eur. J. Pharmacol. 1987, 138, 199-206. (16) Lipp, R.; Schunack, W.; Arrang, J.-M.; Garbarg, M.; Schwartz, J.-C. Synthesis and H₃-Antagonistic Activity of N^{α}-substituted Histamine Derivatives. Xth International Symposium on Medicinal Chemistry (Abstract P-119) Budapest, August 15–19, 1988. (17) Stark, H.; Lipp, R.; Schunack, W.; Arrang, J.-M.; Defontaine, N.;

Schwartz, J.-C. Structural Variations Outgoing from Na-Acylated Histamine Derivatives and Their Influence on H₃-Antagonistic Activity. In

tamine Derivatives and Their Influence on H₃-Antagonistic Activity. In
New Perspectives in Histamine Research, Satellite Symposium of the
XIth International Congress of Pharmacology of IUPHAR (Abstract P40).
Noordwijkerhout, July 6-8, 1990.
(18) Khalaf, Y. S.; Ganellin, C. R.; Hosseini, S. K.; Tertiuk, W.; Arrang,
J.-M.; Defontaine, N. Partial Structures of Thioperamide and Related
H₃-Receptor Histamine Antagonists. XIX Meeting of the European
Histamine Research Society (Abstract, p 38). Kuopio, May 16-20, 1990.

^{*} Author to whom correspondence should be addressed.

[†] Nomenclature of substituted histamine derivatives is based on the method of Black and Ganellin.45

[‡] Presented in part: New Perspectives in Histamine Research, Satellite Symposium of the XIth International Congress of Pharmacology of IUPHAR (Abstract SL07), Noordwijkerhout, July 6-8, 1990. Eur. Pat. Appl. 0 338 939. US Patent 414 923. Institute of Pharmacy, Freie Universität Berlin.


Centre Paul Broca de l'INSERM.

⁽¹⁰⁾ Trzeciakowski, J. P. Inhibition of Guinea Pig Ileum Contractions Mediated by a Class of Receptor Resembling the H₃ Subtype. Pharmacol. Exp. Ther. 1987, 243, 874-880.

⁽¹¹⁾ Arrang, J.-M.; Devaux, B.; Chodkiewicz, J.-P.; Schwartz, J.-C. H₃-Receptors Control Histamine Release in Human Brain. J. Neurochem. 1988, 51, 105-108.

Figure 1. Structure of (αR) - α -methylhistamine.

Scheme I



only inferior activity at other receptors.⁵ Taking into account the biological properties of the latter and, at the same time, considering the well-known stereoselectivity of the third histamine receptor,¹⁹ we decided to synthesize several simple side-chain branched derivatives of the natural ligand histamine as potential H₃ agonists.²⁰ One of these trials resulted in a compound which is slightly more potent than (αR) - α -methylhistamine, being even more selective: $(\alpha R,\beta S)$ - α,β -dimethylhistamine (19) (Scheme III).

Chemistry

Synthesis. Lithium aluminum hydride reduction of 1 led to the amino alcohol 2 which was reduced to the corresponding α -methyl derivative via two pathways (Scheme I). Activation to the corresponding chloromethyl derivative 3 and subsequent hydrogenation was more effective than activation to the iodo derivative 4 and its catalytic reduction to 5. ¹H NMR investigations of 5 showed that it was a mixture of four stereoisomers consisting of 29% threo and 71% erythro configured material (see Experimental Section).

Since pharmacological tests demonstrated the good H_3 agonistic activity of the isomeric mixture of α,β -dimethylhistamine (5), a second synthetic pathway for selective synthesis of the putative active isomer was designed (Scheme II).

The condensation of 6 with ethyl acetate led to the β -keto ester 7, which was converted to the corresponding ketone 8 by treatment with ethanolic KOH. The condensation of 8 with ethyl 2-(diethylphosphono) propionate was carried out in the presence of sodium amide and led to a mixture of three reaction products. The separation of the products was performed via crystallization and column chromatography on silica gel. Thus, the geometric isomers (E)ethyl2-methyl-3-[1-(triphenylmethyl)-1H-imidazol-4-yl]-2-butenoate (10) and (Z)-ethyl 2-methyl-3-[1-(triphenylmethyl)-1H-imidazol-4-yl]-2-butenoate (9) as well as their structural isomer (11) were obtained in pure form. Catalytic reduction of Z-configured 9 led to the erythro racemate 12. After hydrolysis of 12 the intermediately obtained free carboxylic acid was introduced into a Schmidt reaction. This led to the desired amine in form of its erythro-configured racemate 13.

Starting from the E-configured 10 the three racemate 15 was obtained via analogous reaction steps.

Resolution of the Racemic Mixture (Scheme III). Due to the fact that the erythro racemate 13 showed higher H_3 agonistic activity in pharmacological in vitro tests, we decided to resolve it.

Thus, the racemic amine 13 was dissolved in boiling ethanol (50%) and poured into a hot solution of 2 equiv of (2S,3S)-O,O'-ditoluoyltartaric acid (DTTA). Cooling down to ambient temperature led to the acid salt 16, which was recrystallized from ethanol (50%) several times and subsequently transformed into the dihydrobromide 18. The filtrate of the first crystallization of 16 was used to obtain the acid salt 17. Therefore the included amine base was set free and subsequently treated with (2R,3R)-O,O'-ditoluoyltartaric acid. After several recrystallizations the acid salt 17 was transformed into the dihydrobromide 19.

Analysis of Optical Purity (Scheme IV). In order to determine the grade of optical purity of the two enantiomers 18 and 19, the method of Dale et al.^{21,22} was applied. Acylation of the chiral amines with (R)-2methoxy-2-phenylacetyl chloride led to diastereomers which were distinguished by different signals in their ¹H NMR spectra. To apply this technique for checking the quality of the resolution, the diastereomers 20 and 21 were synthesized starting with small amounts of the acid O,O'ditoluoyltartrates 16 and 17. Due to the fact that this purity check was carried out prior to the final conversion of the acid O,O'-ditoluoyltartrates into the corresponding dihydrobromides, it had basically the function of an inprocess control. Application of the latter guaranteed a high level of optical purity for the obtained enantiomers.

Interpreting the ¹H NMR spectra of the diastereomers 20 and 21 shows that the most significant differences with regard to their chemical shifts are displayed by the 1'methyl doublets of 20 (δ = 0.98 ppm) compared to those of 21 (δ = 0.92 ppm, both spectra: 300 MHz, CD₂Cl₂). The total absence of the signal of the opposite diastereomer was required. Meeting this condition, the ¹H NMR spectra of 20 as well as 21 offered evidence of optical purity of each one of the two related amines.

Spiking experiments were performed in order to assess the sensitivity of the ¹H NMR method. Within these studies optical impurities of 2.5% were clearly detected.

⁽¹⁹⁾ Arrang, J.-M.; Schwartz, J.-C.; Schunack, W. Stereoselectivity of the Histamine H₃-Presynaptic Autoreceptor. *Eur. J. Pharmacol.* 1985, 117, 109–114.

⁽²⁰⁾ Arrang, J.-M.; Garbarg, M.; Lipp, R.; Schunack, W.; Schwartz, J.-C.; Stark, H.; unpublished results.

⁽²¹⁾ Dale, J. A.; Mosher, H. S. Nuclear Magnetic Resonance Enantiomer Reagents. Configurational Correlations via Nuclear Magnetic Resonance Chemical Shifts of Diastereomeric Mandelate, O-Methylmandelate, and α -Methoxy- α -trifluoromethylphenylacetate (MTPA) Esters. J. Am. Chem. Soc. 1973, 95, 512–519.

⁽²²⁾ Dale, J. A.; Dull, D. L.; Mosher, H. S. α-Methoxy-α-trifluoromethylphenylacetic Acid, a Versatile Reagent for the Determination of Enantiomeric Composition of Alcohols and Amines. J. Org. Chem. 1969, 34, 2543.

Scheme III

(+)-(25.3R)-5

16

18

Scheme IV

2HB

2 DTTA

R

н

сн,

16. 17


R¹

сн,

20

21 н 14

15



2HBI

19

20, 21

Configuration

2R. 2'S. 3'R

2R. 2'R. 3'S

The side-chain conformation can be described by the torsion angles $\tau_1 = 81.8(5)/81.7(4)$ (mol. 1/mol. 2; for definition of τ_1 , τ_2 , see Figure 3) and $\tau_2 = 64.9(4)/64.0(4)$ in the crystal structure. A similar τ_1 value (84.0) was found in histamine diphosphate monohydrate, but in all X-ray structures of histamine dications previously determined, a trans arrangement was found for τ_2 .^{25,26} The present gauche conformation, however, was observed for the histidine cation²⁷ in L-histidine hydrochloride monohydrate. Results of a force field calculation are shown in a two-dimensional Ramachandran plot versus τ_1 and τ_2 in Figure 3. There are relatively sharp energy minima around

By definition, percent enantiomeric excess equals the percent of the predominant enantiomer in excess of the

R⁴

н

CH3

R³

сн,

н

⁽²⁴⁾ Veidis, M. V.; Palenik, G. J.; Schaffrin, R.; Trotter, J. Crystal Structure of Histamine Diphosphate Monohydrate. J. Chem. Soc. (London) A 1969, 2659–2666. (25) Bonnet, J. J.; Jeannin, Y. Crystallographic Study of the Tetra-

chlorocobaltate(II) of Diprotonated Histamine. Acta Crystallogr. 1973, B28, 1079-1085.

⁽²⁶⁾ Yamane, T.; Ashida, T.; Kakudo, M. The Crystal Structure of Histamine Sulphate Monohydrate. Acta Crystallogr. 1973, B29, 2884-2891

⁽²⁷⁾ Donohue, J.; Caron, A. Refinement of the Crystal Structure of Histidine Hydrochloride Monohydrate. Acta Crystallogr. 1964, 17, 1178-1180.

⁽²³⁾ Keller, E. SCHAKAL86, Program for the Graphic Representation of Molecular and Crystallographic Models; University of Freiburg, Germany, 1986.




Figure 2. Stereo representation²³ of the correct $\alpha R,\beta S$ -enantiomer (19) as derived from the X-ray analysis.




Figure 3. Conformational energy plotted as two-dimensional distribution versus $\tau_1 = N(2)-C(1)-C(6)-C(7)$ and $\tau_2 = C(1)-C(6)-C(7)-N(7)$. The distribution is obtained from molecular mechanics calculations based on the force field implemented in the CHEMX⁴⁶ program package. Contour lines are drawn at 17 kJ/mol intervals. I = absolute minimum. II = conformation of X-ray structure.

 $\tau_1 = \pm 90^{\circ}$; however, a rather broad range of low energy is seen for τ_2 with the absolute minimum at $(\tau_1, \tau_2) = (-100^{\circ}, 140^{\circ})$. The X-ray structure is in a broad hollow next to a second (relative) minimum at $(75^{\circ}, 140^{\circ})$. Obviously there is little energetic constraint in the side-chain conformation, especially along the $C\alpha - C\beta$ bond, and the actual X-ray conformation may largely be influenced by a total number of 10 hydrogen bonds with which the dication is involved.

All nitrogen-bonded H atoms of the two independent molecules act as donors, while the bromine anions are acceptors in different frequencies: Br(1), five times; Br(2) and Br(3), twice; and Br(4), once. The H…Br⁻ contacts are in a range of 2.36 (5) to 2.74 (7) Å, the N…Br⁻ distances vary from 3.275 (4) to 3.541 (4) Å. Since a N…Br⁻ separation of 3.28–3.44 Å is generally considered for N-H…Br⁻ hydrogen bonds,²⁸ one of the contacts found in the crystal structure of 19 must be regarded as a rather weak hydrogen bond.

Biological Results and Discussion

The α,β -dimethylhistamines and their mixtures were tested for H₃ agonistic activity in the model of Arrang et al.,¹ thereby investigating their influence on K⁺-induced histamine release from slices of rat brain cortex. In order to determine the receptor selectivity of the α,β -dimethylhistamines, the mixture of four stereoisomers (5) as well as the pure $\alpha R,\beta S$ -configured amine (19) were additionally tested for H₂ agonism on the spontaneously beating guinea pig right atrium and H₁ agonism on guinea pig ileum (see Table I).

All α,β -dimethylhistamines proved to be full agonists at H_3 receptors. Although they did not show any difference in their intrinsic activity, their relative potencies vary greatly compared with the natural ligand histamine. The mixture of 29% of erythro- and 71% of threo-configured α,β -dimethylhistamine (5), as obtained from the first synthetic pathway, shows about 5-fold the activity of histamine at H_3 receptors. The fact that presently only one chiral compound, (αR) - α -methylhistamine, was known to be more active than 5 was the reason to search for the most potent of the four stereoisomers of this mixture. Thus, the threo- and erythro-configured racemates of α,β dimethylhistamine (15, 13) were synthesized. The erythro racemate proved to be 30-fold as active as the three racemate, thereby showing 10 times the activity of histamine at H_3 receptors (Figure 4). After resolution of the erythro racemate a very high degree of stereoselectivity of H_3 receptors was found for the resulting enantiomers: the $\alpha R,\beta S$ -configured eutomer is 100 times more potent than the $\alpha S,\beta R$ -configured distomer.

These data correspond with earlier results indicating a high degree of stereoselectivity of H₃ receptors for α -branched histamine derivatives. In a series of α -branched histamines the enantiomer with a relative configuration equivalent to L-histidine always proved to be more potent than its opposite enantiomer^{19,7} (e.g. (αR) - α -methylhistamine). Therefore $(\alpha R,\beta S)$ - α,β -dimethylhistamine, being the eutomer, perfectly fits in with these findings.

Furthermore, the high degree of differentiation between the erythro and the threo racemate (13 vs 15), both containing one αR -configured stereocenter, suggests that H₃ receptors have a high degree of stereoselectivity for β -branched histamines, too.

The activity profile of 19 shows that it is 130 000-fold more active at H_3 than at H_1 and H_2 receptors. Therefore 19 is at present not only the most active chiral agonist at H_3 receptors but also the most selective one.

 $(\alpha R,\beta S)$ - α,β -Dimethylhistamine is also found to be a substrate for histamine-N-methyltransferase (EC 2.1.1.8), being one of the enzymes responsible for the catabolism of histamine.^{29,30} The K_m value of the enzyme for 19 was

⁽²⁸⁾ Jeffrey, G. A.; Saenger, W. In Hydrogen Bonding; Jeffrey, G. A., Saenger, W., Eds.; Springer Verlag: Berlin, 1991; p 29.

⁽²⁹⁾ Schayer, R. W. Catabolism of Histamine in vivo. In Handbook of Experimental Pharmacology; Rocha e Silva, M., Ed.; Springer-Verlag: Berlin, 1966; Vol. 18, pp 672–683.

compd	configuration	Agonism					
		H ₃ : inhibn of [³ H]histamine release		H ₂ : atrial rate		H ₁ : Ileum contraction	
		EC ₅₀	ia	EC 50	ia	EC50	ia
histamine		$6.2 \pm 1.4 \cdot 10^{-8}$	1	$1.0 \pm 0.3 \cdot 10^{-8}$	1	$1.4 \pm 0.9 \cdot 10^{-7}$	1
5	29% αR,βS; αS,βR 71% αR,βR; αS,βS	$1.2 \pm 0.3 \cdot 10^{-8}$	1	9.4 ± 0.6•10 ⁻⁴	0.66	$1.8 \pm 0.5 \cdot 10^{-4}$	0.94
13 (erythro)	$\alpha R,\beta S; \alpha S,\beta R$	$6.2 \pm 1.9 \cdot 10^{-9}$	1	ni	ni		
15 (threo)	$\alpha R,\beta R; \alpha S,\beta S$	$1.9 \pm 1.2 \cdot 10^{-7}$	1	ni		ni	
18	$\alpha S, \beta R$	$3.5 \pm 1.7 \cdot 10^{-7}$	1	ni		ni	
19	$\alpha R,\beta S$	3.4 ± 2.0•10 ^{−8}	1	$4.1 \pm 2.8 \cdot 10^{-4}$	0.86	$4.2 \pm 2.5 \cdot 10^{-4}$	0.56

^a All EC₅₀ values are given as $\dot{x} \pm$ sem and were calculated from data of three or four independent pharmacological in vitro experiments. Calculation of EC₅₀ values at H₃ receptors was carried out according to the method of Parker and Waud⁴⁷ while statistical evaluation of the data for H₁ and H₂ agonism was carried out according to the method of Sachs.⁴⁸




Figure 4. H₃ agonism of α,β -dimethylhistamine, measured as effect on inhibition of K⁺-evoked [³H]histamine release from slices of rat brain cortex. Histamine = 100%. The first column represents the activity of a mixture of 29% erythro- and 71% threo- α,β -dimethylhistamine.

2.8 μ M and the V_{max} , 1.7 nmol/mg per h. These kinetic parameters are close to those reported for histamine,^{31,32} which suggests that 19 can be methylated as effectively as histamine.

Experimental Section

Chemistry. General Procedures. Melting points are not corrected and were determined by using a Büchi 512 Dr. Tottoli apparatus. ¹H NMR spectra were recorded on a Bruker WM 250 or alternatively a Bruker WC 300 spectrometer with TMS as internal standard. A Perkin-Elmer 241 MC polarimeter was used. MS spectra were recorded using Finnigan MAT CH7A (70 eV), Finnigan MAT 711 (80 eV), Kratos MS 25 RF (70 eV) or, in case of ⁺FAB spectra, a Finnigan MAT CH5DF instrument (xenon, DMSO/glycerol). Elemental analyses were performed on Perkin-Elmer 240B and Perkin-Elmer 240C instruments. Thin-layer chromatography (TLC) was performed on silica gel F₂₅₄ plates (Merck). Column chromatography was carried out using silica gel 63-200 μ m (Machery & Nagel).

2-Amino-3-(1H-imidazol-4-yl)butanol (2). Compound 1 (Methyl 2-amino-3-(1H-imidazol-4-yl) butanoate dihydrochloride, prepared according to the method of Kelley et al.³³) (7.7 g, 30 mmol) was added at 0 °C to a stirred suspension of 3.4 g (90 mmol) of lithium aluminum hydride in 125 mL of THF. Subsequently, the mixture was refluxed for 3 h, cooled to 0 °C and hydrolyzed by addition of 6.5 mL of H_2O in 15 mL of THF. Stirring with 20 mL of 5 N NaOH afforded a coarse-grained precipitate which was filtered off and extracted by means of 100 mL of EtOH in 3 portions. The concentration of the fractions afforded an oil which was treated with anhydrous EtOH to separate inorganic material. Filtration and evaporation yielded 4 g (85.9%) of 2, which was converted into the oily dihydrochloride. An analytical sample was converted into the dipicrate and recrystallized from EtOH-H₂O. Mp: 168 °C. MS (70 eV): m/z 155 (M⁺⁺, <1), 125 (6), 95 (100), 41 (27). ¹H NMR (250 MHz, [D₆]DMSO): δ 9.12 (1 H, s, imidazole-2-H), 8.63 (4 H, s, 2-pic-3,5-H), 7.87 (3 H, br, exchangeable by D_2O , NH_3^+), 7.56-7.49 (1 H, m, imidazole-5-H), 3.79-3.26 (5 H, m, 1 H exchangeable by D_2O , CHCHCH₂OH, 1.32 (3 H, d, J = 6.1 Hz, CH₃). Anal. $(C_7H_{13}N_3O\cdot 2C_6H_3N_3O_7)$ C, H, N.

1-Chloro-3-(1*H*-imidazol-4-yl)-2-butanamine Dihydrochloride (3). Compound 2-2HCl (3 g, 13.2 mmol) was dissolved in a mixture of 25 mL of tetramethylene sulfone and 10 mL of SOCl₂ and stirred for 12 h at ambient temperature. Dropwise addition of 200 mL of CHCl₃ afforded 2.87 g (88.2%) of 3 as a hygroscopic precipitate. MS (70 eV): m/z 173 (M⁺⁺, <1), 137 (7), 96 (98), 95 (100). ¹H NMR (250 MHz, [D₆]DMSO): δ 14.7 (2 H, br, exchangeable by D₂O, 2 imidazole-NH), 9.15 (1 H, s, imidazole-2-H), 8.75 (3 H, br, exchangeable by D₂O, NH₃⁺), 7.56-7.49 (1 H, m, imidazole-5-H), 4.03 (2 H, d, J = 7 Hz, CH₂Cl), 3.86-3.77 (1 H, m, CHNH₃⁺), 3.55-3.42 (1 H, m, CH-imidazole), 1.37 (3 H, d, J = 7 Hz, CH₃). An analytical sample was converted into the dipicrate and recrystallized from EtOH-H₂O. Mp: 196-198 °C. Anal. (C₇H₁₂ClN₃·2C₆H₃N₃O₇) C, H, N.

3-(1*H*-Imidazol-4-yl)-1-iodo-2-butanamine Dihydriodide (4). Compound 2 (12.7 g) was refluxed for 3 d in 250 mL of 57% HI. After evaporation, the resulting oil was crystallized by means of dimethoxyethane, yielding 17.88 g (41.9%) of 4 in the form of white crystals. Mp: 204 °C. +FAB-MS: 267/266 ([M + H]⁺, 9/100), 133 (33), 123 (46), 99 (44). ¹H NMR (300 MHz, [D₆]-DMSO): δ 9.21 (1 H, s, imidazole-2-H), 8.12 (3 H, br, exchangeable by D₂O, NH₃⁺), 7.57 (1 H, s, imidazole-5-H), 3.51 (2 H, J = 3.7 Hz, CH₂), 3.44-3.35 (1 H, m, CHN), 3.27-3.13 (1 H, m, imidazole-CH), 1.27 (3 H, d, J = 7 Hz, CH₃). Anal. (C₇H₁₂IN₃·2HI) C, H, N.

3-(1H)-Imidazol-4-yl)-2-butanamine (5). Method A. Compound 4 (3.11 g, 6.0 mmol) was dissolved in 250 mL of 25% acetic acid. Pd-Ca₂CO₃ (1.5 g, 5%) was added and the mixture was hydrogenated for 48 h at 10 bar and ambient temperature. After evaporation, the residue was alkalized by addition of sufficient 6 N Na₂CO₃. Evaporation, extraction of the semisolid residue by means of EtOH, and column chromatography using silica gel

⁽³⁰⁾ Brown, D.; Tomshick, R.; Axelrod, J. The Distribution and Properties of a Histamine-methylating Enzyme. J. Biol. Chem. 1959, 224, 2948-2950.

⁽³¹⁾ Baudry, M.; Chast, F.; Schwartz, J. C. Studies on S-Adenosylhomocysteine Inhibition of Histamine Transmethylation in Brain. J. Neurochem. 1973, 20, 13-21.

⁽³²⁾ Matuszewska, B.; Borchardt, R. T. Guinea Pig Brain Histamine N-Methyltransferase: Purification and Partial Characterization. J. Neurochem. 1983, 41, 113-118.

⁽³³⁾ Kelley, J. L.; Miller, C. A.; McLean, E. W. Attempted Inhibition of Histidine Decarboxylase with β -Alkyl Analogues of Histidine. J. Med. Chem. 1977, 20, 721–723.

 $(62-200 \,\mu\text{m}; \text{eluent}, \text{CHCl}_3-\text{MeOH saturated by NH}_3(9+1))$ led to 0.42 g of 5 as a colorless oil.

Method B: A mixture of 2 g (8.1 mmol) of 3, 1.3 g (16.2 mmol) of NaOAc and 100 mL of 10% AcOH, was hydrogenated over 0.5 g Pd-C (10%) for 10 d at 10 bar and ambient temperature. The catalyst was removed by filtration and the filtrate brought to pH 1 by addition of concentrated HCl. After evaporation the oily residue was dissolved in dry EtOH and inorganic material was removed by filtration. By addition of petroleum ether, 5 crystallized as the dihydrochloride. Recrystallization from MeOH-MeCN yielded 0.72 g (40.4%) of 5.2HCl.0.25MeOH as colorless crystals. Mp: 249-254 °C dec. MS (70 eV): m/z 140 (11), 139 (M⁺, 1), 124 (14), 96 (95), 81 (35), 44 (100). ¹H NMR (250 MHz, $[D_6]$ DMSO): δ 14.76 (2 H, br, exchangeable by D_2O , 2 imidazole-NH), 9.12 (1 H, s, imidazole-2-H) 8.36 (3 H, br, exchangeable by D₂O, NH₃⁺), 7.58 (0.71 H, s erythro-imidazole-5-H), 7.51 (0.29 H, s, threo-imidazole-5-H), 3.40 (1 H, m, CHNH₃⁺), 3.28 (1 H, m, CH-imidazole), 1.30 (3 H, m, imidazole-CHCH₃), 1.19 (0.71.3 H, d, J = 6.5 Hz, threo-NCHCH₃), 1.12 $(0.29.3 \text{ H}, \text{d}, J = 6.5 \text{ Hz}, erythro-NCHCH_3)$. Anal. $(C_7H_{13}N_3)$. 2HCl·0.25CH₄O) C, H, N.

Ethyl 3-Oxo-3-[1-(triphenylmethyl)-1H-imidazol-4-yl]propanoate (7). Methyl 1-(triphenylmethyl)-1H-imidazole-4carboxylate (6, prepared according to the method of Belgadere et al.³⁴) (202.7 g, 0.55 mol) was dissolved in 0.8 L of dry toluene at 85 °C. NaH (44 g, 1.1 mol, 60 % dispersion in mineral oil) was added. To the stirred solution were added dropwise 96.9 g (1.1 mol) of AcOEt within 2 h. The mixture was allowed to react overnight at 70 °C. Subsequently the toluene was removed under reduced pressure. The resulting mixture was introduced into the following step without purification. For analytical purposes a small amount of the brown oily residue was dissolved in CH2-Cl₂. Washing with 2 M NH₄Cl and H₂O, drying over Na₂SO₄, and evaporation led to an oil. Crystallization with Et₂O and recrystallization from EtOH-Et₂O afforded 7 as white crystals. Mp: 136-139 °C. MS (80 eV): m/z (M⁺, <1), 344 (19), 243 (100). ¹H NMR (60 MHz, CDCl₃): δ 7.62 (1 H, d, J = 1.4 Hz, imidazole-2-H), 7.55-6.99 (16 H, m, aryl), 4.61 (2 H, q, J = 6.1 H_z, CH_2O), 3.99 (2 H, s, CH_2CO), 1.24 (3 H, t, $J = 6.1 H_z, CH_2CH_3$). Anal. $(C_{27}H_{24}N_2O_3)$ C, H, N.

1-[1-(Triphenylmethyl)-1*H*-imida zol-4-yl]ethanone (8). The residue as described above was dissolved in a mixture of 75 g of KOH, 140 mL of H₂O and 1.3 L of EtOH. The solution was heated under reflux for 10 h. Solid material was removed by filtration. After evaporation and dissolving in CH₂Cl₂, it was washed three times with 400 mL of H₂O, dried over Na₂SO₄, and evaporated. Stirring and addition of Et₂O afforded 115.3 g of 8 (59.5% based on 6). An analytical sample was recrystallized from EtOH. Mp: 164-165 °C. MS (80 eV): m/z 352 (M⁺⁺, <1), 244 (22), 243 (100), 183 (85). ¹H NMR (300 MHz, CDCl₃): δ 7.45-7.20 (17 H, m, aryl-H), 3.06 (3 H, s, CH₃). Anal. (C₂₄H₂₀N₂O) C, H, N.

(Z)-Ethyl 2-Methyl-3-[1-(triphenylmethyl)-1H-imidazol-4-yl]-2-butenoate (9). NaNH₂ (11.7 g, 0.3 mol) was suspended in 300 mL of THF under nitrogen. Ethyl 2-(diethylphosphono)propionate (71.5g, 0.3 mol) was added dropwise to the mixture, which was kept at ambient temperature for 2 h subsequently. 8 (30.5 g, 86.5 mol) was added and the mixture was held under reflux for 16 h. Evaporation and dissolving in 1 L of CHCl₃iPrOH (3 + 1) was followed by washing three times with H₂O. Drying over Na_2SO_4 and evaporation resulted in an oil which mainly consisted of (E)-ethyl 2-methyl-3-[1-(triphenylmethyl)-1H-imidazol-4-yl]-2-butenoate (10). Treating this residue with Et_2O afforded 10.9 g of a solid material mainly bearing the Z-isomer. Purification via column chromatography (silica gel $63-200 \ \mu$ m, petroleum ether-Et₂O (2 + 3)) led to 5.6 g (14.8%) of 9 as a white solid. An analytical amount was recrystallized from Et₂O-EtOH, resulting in colorless crystals. Mp: 166-168 °C. MS (80 eV): m/z 436 (M⁺⁺, 2), 244 (20), 243 (100), 165 (23). ¹H NMR (300 MHz, CDCl₃): δ 7.58-7.11 (16 H, m, aryl-H), 6.76 $(1 \text{ H}, d, J = 1 \text{ Hz}, \text{imidazole-5-H}), 4.07 (2 \text{ H}, q, J = 7.1 \text{ Hz}, \text{CH}_2\text{O}),$ 1.98 (6 H, s, $H_3CC=CCH_3$), 1.17 (3 H, t, J = 7.1 Hz, CH_2CH_3). Anal. ($C_{29}H_{29}N_2O_2$) C, H, N.

(E)-Ethyl 2-Methyl-3-[1-(triphenylmethyl)-1*H*-imidazol-4-yl]-2-butenoate (10). The above mentioned solution of the *E*-isomer was evaporated. The residue was purified using column chromatography (silica gel 63-200 μ m, petroleum ether-Et₂O (1 + 1)). The resulting oil, 10 (15.5 g, 41.8%), crystallized while standing at ambient temperature. An analytical sample was recrystallized from cyclohexane. Mp: 103-104 °C. MS (80 eV): m/z 436 (M⁺⁺, <1), 391 (<1), 243 (100), 165 (23). ¹H NMR (300 MHz, CDCl₃): δ 7.48 (1 H, d, J = 1.3 Hz, imidazole-2-H), 7.35-7.15 (15 H, m, 3 phenyl), 6.82 (1 H, d, J = 1.3 Hz, imidazole-5-H), 4.22 (2 H, q, J = 7.1 Hz, CH₂), 2.28 (3 H, d, J = 1.3 Hz, α -CH₃), 2.02 (3 H, d, J = 1.3 Hz, β -CH₃), 1.31 (3 H, t, J = 7.1 Hz, CH₂CH₃). Anal. (C₂₉H₂₈N₂O₂) C, H, N.

Ethyl 2-Methyl-3-[1-(triphenylmethyl)-1*H*-imidazol-4yl]-3-butenoate (11). The last fractions obtained from column chromatography described above afforded 1.23 g (3.3%) 11 which was recrystallized from EtOH. Mp: 152 °C. MS (80 eV): m/z436 (M⁺⁺, 4), 361 (1), 243 (100), 165 (99). ¹H NMR (300 MHz, CDCl₃): δ 7.41 (1 H, d, J = 1.2 Hz, imidazole-2-H), 7.34-7.11 (15 H, m, 3 phenyl), 6.88 (1 H, imidazole-5-H), 5.83 (1 H, s, ==CH₂ (Z)), 5.11 (1 H, s, ==CH₂ (E)), 4.01 (2 H, m, OCH₂), 3.53 (1 H, q, J = 7.1 Hz, CH), 1.38 (3 H, d, J = 7.1 Hz, CHCH₃), 1.11 (3 H, t, J = 7.1 Hz, CH₂CH₃). Anal. (C₂₉H₂₈N₂O₂) C, H, N.

 $(2R^*, 3S^*)$ - (\pm) -Ethyl 3-(1H-Imidazol-4-yl)-2-methylbutanoate (12). Compound 9 (10.2 g, 23.4 mol) was dissolved in 350 mL of THF; 1.5 g of Pd-C (10%) was added. The mixture was hydrogenated for 3 d at ambient temperature and 10 bar. After removal of the catalyst by filtration the solution was evaporated to dryness. The residue was purified by column chromatography (silica gel 63-200 μ m; eluent 1, Et₂O; eluent 2, CHCl₃-MeOH saturated with NH_3 (1 + 1)), leading to 3.9 g (84.9%) of 12 as a colorless oil. A small amount was converted into the hydrogen maleate, which was recrystallized from EtOH-Et₂O. Mp: 91-94 °C. MS (80 eV): m/z 196 (M⁺⁺, 11), 123 (30), 95 (100). ¹H NMR (300 MHz, [D₆]DMSO): δ 8.88 (1 H, s, imidazole-2-H), 7.46 (1 H, s, imidazole-5-H), 6.05 (2 H, s, CH=CH), 4.08 (2 H, q, J = 6.7 Hz, CH₂O), 3.10 (1 H, dq, $J_1 = J_2 = 7$ Hz, CHC=O), 2.70 (1 H, dq, $J_1 = J_2 = 7$ Hz, CH-imidazole), 1.22-1.13 (6 H, m, CH_2CH_3), β -CH₃), 0.95 (3 H, d, J = 7 Hz, α -CH₃). Anal. $(C_{10}H_{16}N_2O_2 \cdot C_4H_4O_4)$ C, H, N.

 $(2R^*, 3S^*) - (\pm) - 3 - (1H - Imidazol - 4 - yl) - 2 - butanamine$ (13). Compound 12 (3.8 g, 19.4 mol) was dissolved in 60 mL of 6 M HCl and heated under reflux for 5 h. Evaporation afforded erythro-3-(1H-imidazol-4-yl)-2-methylbutanoic acid hydrochloride as a hygroscopic oil which was dissolved in 20 mL of concentrated H₂SO₄. Subsequently 125 mL of CHCl₃ was added. The mixture was stirred and 5.85 g (90 mmol) of NaN₃ was added over 1 h at 0 °C. The reaction mixture was held at 45 °C for 14 h. After addition of some ice the organic layer was removed. The aqueous phase was brought to pH 8.5 and evaporated to dryness. Soxhleting the resulting solid material for 3 h by means of iBuOH afforded the title compound as a crude oil, which was purified via column chromatography (silica gel 63-200 µm; eluent, CHCl₃-MeOH saturated with NH_3 (85 + 15)) affording 2.32 g (85.9%) of 13 as a colorless oil. $FAB-MS (13-2HCl) m/z 140 ([M + H]^+,$ 14), 123 (5), 93 (100), 74 (28). ¹H NMR (13-2HCl, 300 MHz, [D₆]DMSO): δ 9.10 (1 H, s, imidazole-2-H), 8.32 (3 H, br, exchangeable by D₂O, NH₃⁺), 7.55 (1 H, s, imidazole-5-H), 3.42-3.37 (1 H, m, CHNH₃⁺), 3.17–3.12 (1 H, m, CH-imidazole), 1.33 (3 H, J = 7.2 Hz, β -CH₃), 1.12 (3 H, d, J = 6.6 Hz, α -CH₃). An analytical sample was converted into the dipicrate and recrystallized from EtOH. Mp: 228-232 °C. Anal. (C₇H₁₃N₃. 2C₆H₃N₃O₇) C, H, N.

(2*R**,3*R**)-(±)-Ethyl 3-(1*H*-Imidazol-4-yl)-2-methylbutanoate (14). Compound 14 was synthesized similarly to 12. Starting from 10, compound 14·2HCl was obtained in 87.2% yield. An analytical sample was converted into the dihydrogen maleate. Mp: 79-81 °C (EtOH-Et₂O). MS (80 eV): m/z 196 (M⁺⁺, 10), 181 (4), 135 (5), 123 (30), 95 (100), 68 (27). ¹H NMR (300 MHz, [D₆]DMSO): δ 8.87 (1 H, s, imidazole-2-H), 7.41 (1 H, s, imidazole-5-H), 6.06 (2 H, s, CH=CH), 4.01 (2 H, q, J = 7 Hz, CH₂O), 3.22 (1 H, dq, $J_1 = J_2 = 7$ Hz, CHC=O), 2.81 (1 H, dq, $J_1 = J_2 = 7$ Hz, CH-imidazole), 1.21 (3 H, d, J = 7 Hz, β -CH₃), 1.10 (3 H, t,

⁽³⁴⁾ Belgadere, E.; Bossio, R.; Parrini, V.; Pepino, R. Imidazole Derivatives with Potential Biological Activity. Arzneim.-Forsch. 1980, 30, 1051-1056.

J = 7 Hz, CH₂CH₃), 0.95 (3 H, d, J = 7 Hz, α -CH₃). Anal. $(C_{10}H_{16}N_2O_2 C_4H_4O_4) C, H, N.$

(2R*,3R*)-(±)-3-(1H-Imidazol-4-yl)-2-butanamine (15). The preparation of 15 was carried out analogously to the synthesis of 13. Starting with 14, 15.2HCl was obtained in 39.5% yield. Mp: 266-269 °C (EtOH). +FAB-MS: m/z 140 ([M + H]+, 40), 123 (8), 93 (100), 74 (31). ¹H NMR (13 2HCl, 300 MHz, [D₆]-DMSO): δ 14.78 (2 H, br, exchangeable by D₂O, 2 imidazole-NH), 9.12 (1 H, d, J = 1 Hz, imidazole-2-H), 8.37 (3 H, br, exchangeable by D_2O , NH_3^+), 7.51 (1 H, d, J = 1 Hz, imidazole-5-H), 3.57 (1 H, br, CHNH₃⁺), 3.33 (1 H, dq, $J_1 = J_2 = 7$ Hz, CH-imidazole), 1.32 (3 H, J = 7.2 Hz, β -CH₃), 1.19 (3 H, d, J =6.5 Hz, α -CH₃). Anal. (C₇H₁₃N₃·2HCl) C, H, N.

(+)-(2S,3R)-3-(1H-Imidazol-4-yl)-2-butanamine Bis[hydrogen (25,35)-O,O'-ditoluoyltartrate] Monohydrate (16). Compound 13 (0.56 g, 4 mmol) was dissolved in 30 mL of hot EtOH-H₂O (1 + 1) and added to a hot solution of 3.13 g (8.1 mmol) of (2S,3S)-O,O'-ditoluoyltartaric acid in 80 mL of hot EtOH- $H_2O(1 + 1)$. After being left at ambient temperature for 3 d, the resulting white crystals were recrystallized several times from EtOH-H₂O (1 + 1) until the ¹H NMR test (see Analysis of Optical Purity and the method for 20) gave evidence of ee > 95%. Yield: 0.79 g (42.5%) of 16. Mp: 181 °C. ¹H NMR (250 MHz, [D₆]DMSO): δ 7.87-7.84 (9 H, m, 4 phenyl-2,6-H, imidazole-2-H), 7.34 (8 H, d, J = 8 Hz, 4 phenyl-3,5-H), 6.99 (1 H, s, imidazole-5-H), 5.69 (4 H, s, 2 OCHCHO), 3.38-3.31 (1 H, m, CHNH₃⁺), 3.08-2.97 (1 H, m, CH-imidazole), 2.37 (12 H, s, 4 phenyl-CH₃), 1.14 (3 H, d, J = 7.1 Hz, β -CH₃), 0.95 (3 H, d, J = 6.5 Hz, α -CH₃). $[\alpha]^{20}_{D} = +110.6 \ (2)^{\circ} \ (c = 0.1, MeOH).$ Anal. $(C_7H_{13}N_3)^{\circ}$ $2C_{20}H_{18}O_8 \cdot H_2O)$ C, H, N.

(2S,3R)-(-)-3-(1H-Imidazol-4-yl)-2-butanamine Dihydrobromide (18). Compound 16 (0.77 g, 0.83 mmol) was dissolved in 60 mL of EtOH-H₂O (2 + 1), and 0.5 mL of 47% HBr was added. Evaporation and redissolving in 20 mL of H₂O plus 20 mL of CH_2Cl_2 were followed by extraction (4×) with 20 mL of CH_2Cl_2 . The aqueous solution was evaporated and delivered from excess HBr. Adding Et₂O and iPrOH followed by stirring afforded 0.18 g (72%) of 18. Mp: 226-227 °C (EtOH-Et₂O). The ¹H NMR spectrum of 18 was entirely the same as that of 13. $[\alpha]^{20}_{D}$: -6.3° (c = 0.5, H₂O). Anal. (C₇H₁₃N₃·2HBr) C, H, N.

(-)-(2R,3S)-3-(1H-Imidazol-4-yl)-2-butanamine Bis[hydrogen (2R,3R)-O,O'-ditoluoyltartrate] Monohydrate (17). The filtrate of the first crystallization of 18 was evaporated to dryness and converted into the dihydrobromide. Dissolving in dry EtOH and adding an equivalent amount of KOCMe3 resulted, after filtration and evaporation, in 0.17 g (1.2 mmol) of the free base. The latter was dissolved in 10 mL of hot EtOH- H_2O (1 + 1) and given to a solution of 1.07 g (2.5 mmol) of (2R,3R)-O,O'-ditoluoyltartaric acid in 30 mL of hot EtOH-H₂O (1 + 1). After 3 d at ambient temperature the obtained white crystals were recrystallized from EtOH- $H_2O(1 + 1)$, until the ¹H NMR test (see Analysis of Optical Purity and the method for 21) gave evidence of ee >95%, affording 0.21 g of 17 (11.3% based on the educt in 16). Mp: 181 °C. ¹H NMR of 17 proved to be the same as that of 16. $[\alpha]^{20}D$: -109.4° (c = 0.1, MeOH). Anal. $(C_7H_{13}N_3 \cdot 2C_{20}H_{18}O_8 \cdot H_2O)$ C, H, N.

(2R,3S)-(+)-3-(1H-Imidazol-4-yl)-2-butanamine Dihydrobromide (19). Compound 17 (0.2 g, 0.22 mmol) was converted into the dihydrobromide in the way described for 18, affording 60 mg (86.7%) of 19. Mp: 226-227 °C. The 1H NMR of 19 was the same as that of 18. $[\alpha]^{20}_{D}$: 6.2° (c = 0.4, H₂O). Anal. (C7H13N3·2HBr) C, H, N.

(2R,2'S,3'R)-N-[3-(1H-Imidazol-4-yl)-2-butyl]-2-methoxy-2-phenylacetamide (20). Dissolution of 0.1 mmol of 16 in 10 mL of EtOH, addition of 0.1 mL of 47% HBr, and evaporation to dryness were followed by dissolution in H₂O and washing with H_2O four times. Addition of 0.5 mL of 1 M NaOH, 1 mL of CH_2Cl_2 and 0.25 mmol of (R)-2-methoxy-2-phenylacetyl chloride as well as shaking for 5 min afforded 20 as a solution in CH_2Cl_2 . This solution was purified using TLC (one $20 \text{ cm} \times 20 \text{ cm}$ sheet of silica gel $60 F_{254}$, Merck) and CHCl₃-MeOH (19 + 1) in ammonia atmosphere as eluent. The zone which contained the product $(R_f = 0.66)$ was scraped off and eluted by 3×3 mL of EtOH. Evaporation to dryness was followed by redissolving in CH₂Cl₂, filtration, and final evaporation. The resulting oily 20 was directly used for ¹H NMR purposes. ¹H NMR (300 MHz, CD_2Cl_2): δ 7.82

(1 H, exchangeable by D_2O , d, J = 8.4 Hz, NH-CO), 7.63 (1 H, s, imidazole-2-H), 7.35-7.31 (5 H, m, phenyl), 6.72 (1 H, s, imidazole-5-H), 4.57 (1 H, s, CHO), 4.14 (1 H, s, CHNHCO), 3.33 $(3 \text{ H}, \text{ s}, \text{OCH}_3), 2.97 (1 \text{ H}, \text{ t}, J = 5.9 \text{ Hz}, \text{CH-imidazole}), 1.19 (3 \text{ CH-imidazole})$ H, d, J = 7 Hz, 2'-CH₈), 0.98 (3 H, d, J = 6.5 Hz, 1'-CH₈).

(2R,2'R,3'S)-N-[3-(1H-Imidazol-4-yl)-2-butyl]-2-methoxy-2-phenylacetamide (21). Compound 21 was analogously prepared as described for 20 but starting from 17. ¹H NMR (300 MHz, CD₂Cl₂): δ 7.81 (1 H, exchangeable by D₂O, d, J = 8.4 Hz, NHCO), 7.59 (1 H, s, imidazole-2-H), 7.35 (5 H, s, phenyl), 6.82 (1 H, s, imidazole-5-H), 4.57 (1 H, s, CHO), 4.14 (1 H, s, CHNHCO), $3.36 (3 H, s, OCH_3), 3.03 (1 H, t, J = 5.9 Hz, CH-imidazole), 1.27$ $(3 \text{ H}, d, J = 6.9 \text{ Hz}, 2'-CH_3), 0.92 (3 \text{ H}, d, J = 6.5 \text{ Hz}, 1'-CH_3).$

Single Crystal X-ray Analysis. Crystals of C7H13N3.2HBr (19.2HBr) were grown from EtOH-Et₂O. Precise lattice parameters (from 120 high-order reflections with $20^\circ \le 2\theta \le 50^\circ$) and three-dimensional intensity data were measured on a Stoe diffractometer using Ni-filtered CuK α -radiation ($\lambda = 1.5418$ Å). A single crystal with approximate dimensions $0.35 \times 0.08 \times 0.07$ mm was used to collect the intensity data of 4180 reflections of one hemisphere ($\theta \leq 64^{\circ}$; $\pm h$; $\pm k$; l) by using the ω -2 θ scan technique. No significant intensity variations monitored via two check reflections were observed. The intensity data set was corrected for Lorentz and polarization effects. Merging after analytical absorption correction gave 3685 unique reflections (R_{int} = 0.78%, R_{σ} = 0.84%), of which 57 reflections with $I < 2\sigma(I)$ were considered unobserved. Friedel-related reflections were not merged.

Crystal Data. Molecular formula, $C_7H_{13}N_3 \cdot 2HBr$ ($M_7 =$ 301.0); space group, monoclinic $P2_1$; unit cell, a = 11.352 (2) Å, b = 11.881 (2) Å, c = 8.992 (2) Å, $\beta = 113.16$ (2)°, V = 1115.0 Å³, $Z = 4, \rho_x = 1.793 \text{ g cm}^{-3}, \rho_{exp} = 1.81 \text{ g cm}^{-3}, \mu(CuK\alpha) = 98.84 \text{ cm}^{-1}.$ Phase determination was made with direct methods (program SHELXS8635); refinement was done with the corresponding leastsquares programs of the XTAL program system (version 2.2. 1987³⁶). All hydrogens were located from difference syntheses. A $1/\sigma^2(F_o)$ weighting scheme was used; $\sigma(F_o)$ was from counting statistics. No significant peaks or holes were seen in a final difference Fourier map. After convergence, R values of R = 1.91%and $R_w = 1.9\%$ were obtained for the $\alpha R_{,\beta}S$ -enantiomer, when anomalous dispersion corrections were considered for all nonhydrogen atoms with the corresponding values for $\Delta f'$ and $\Delta f''$ from the International Tables for X-ray Crystallography, Vol. IV.³⁷ For the structure of the opposite enantiomer R = 2.62%and $R_w = 2.9\%$ were found.³⁸ The R value ratios R = R(-)/R(+)of 1.372 for the nonweighted and 1.532 for the weighted R values are extremely high. Hence, from extrapolation of the corresponding significance tables given by Hamilton,³⁹ a confidence level of more than 99.9% can be estimated, so that the absolute configuration of 19 as the $\alpha R, \beta S$ enantiomer is safe at least within **99.9**%

Pharmacology. Experiments with Slices of Rat Brain Cortex.¹ Male Wistar rats (170–190g) were killed by decapitation and the brains were immediately removed. Slices (0.3 mm thick) from cerebral cortex were preincubated for 30 min with [3H]-L-histidine (0.3 μ M). After extensive washings, aliquots of the slice suspension (2-3 mg of protein) were incubated at 37 °C for 2 min in the presence of 2 or 30 mM KCl (final concentration). When required, slices were preincubated for 5 min before the depolarizing stimulus in the presence of the various drugs tested as agonists. Incubations were stopped by rapid centrifugation, and [3H] histamine levels present in tissue and medium were quantified as described.1

⁽³⁵⁾ Sheldrick, G. M. In Crystallographic Computing 3; Sheldrick, G. M., Krüger, C., Goddard, R., Eds.; Oxford University Press: Oxford 1985; pp 175-198.

⁽³⁶⁾ Stewart, J. M.; Hall, S. R., Eds.; XTAL Program System 2.2, User's Manual; Universities of Western Australia and Maryland, 1987. (37) Ibers, J. A.; Hamilton, W. C., Eds.; International Tables for X-ray

Crystallography; Kynoch Press: Birmingham, England, 1974; Vol. IV, p

⁽³⁸⁾ Rogers, G. On the Application of Hamilton's Ratio Test to the Assignment of Absolute Configuration and an Alternative Test. Acta Crystallogr. 1981, A37, 734-741. (39) Hamilton, W. C. Significance Test on the Crystallographic R

Factor. Acta Crystallogr. 1965, 18, 502-510.

A Novel Highly Potent Histamine H₃ Receptor Agonist

Experiments with the Isolated Spontaneously Beating Guinea Pig Right Atrium.⁴⁰ Male guinea pigs (350-500 g) were killed by a blow to the head. The heart was removed and incubated in McEvan's solution⁴¹ at 32.5 °C which was gassed with oxygen containing 5% CO₂. The right atrium was separated, placed in a 20-mL organ bath containing McEvan's solution as described above. The latter was continuously substituted during the equilibration time of 1 h. The obtained isometric impulses were recorded by a heart frequency meter. Each preparation was used only for one single test. Three or four experiments were conducted with each compound. To test the H₂ agonistic activity, histamine standard curves (10-7-10-5 M concentration in the bath) were recorded using a cumulative technique. After thoroughly washing the preparation from histamine the potential H₂ agonist was tested by recording an entire concentrationresponse curve.

Experiments with the Isolated Guinea Pig Heum. Male guinea pigs (350-500 g) were killed by a blow to the head. Pieces of the ileum 3 cm in length were incubated in a 20-mL organ bath containing Tyrode solution at 37 °C. Oxygen containing 5% CO₂ was bubbled through the solution. Contraction effects were isotonically recorded. To determine the H₁ agonistic activity of a compound, a histamine standard curve was recorded first. Therefore histamine concentration was geometrically increased in the bath until maximal contraction of the ileum was reached.⁴² Following thorough washing of the preparation, a concentrationresponse curve of the potential agonist was recorded in the same manner.

Experiments with Histamine N-Methyltransferase. Histamine N-methyltransferase activity was quantified by measuring the conversion of histamine into $[^{3}H]$ - τ -methylhistamine using

[³H]-S-adenosylmethionine as a [³H]methyl donor. The enzyme was purified from rat kidney according to the method of Bowsher et al.,⁴³ slightly modified as by Garbarg et al.,⁴⁴ ($\alpha R,\beta S$)- α,β -Dimethylhistamine in increasing concentrations was incubated with the enzyme and a mixture of unlabeled and tritiated S-adenosylmethionine (5 μ M final concentration) for 1 h at 25 °C. The reaction was stopped by addition of perchloric acid (0.4 N final concentration) followed by NaOH (1 N final concentration). [³H]- τ -Methylhistamine was extracted into tolueneisoamyl alcohol (3 + 2) and quantified by liquid scintillation spectrometry.

Acknowledgment. We are grateful to Agnés Rouleau for technical assistance. Support of this work by the Verband der Chemischen Industrie is greatly acknowledged.

Supplementary Material Available: X-ray data including atomic coordinates, anisotropic displacement parameters, distances and angles, hydrogen bond distances for compound 19.2HBr (7 pages); observed and calculated structure factors (33 pages). Ordering information is given on any current masthead page.

⁽⁴⁰⁾ Lennartz, H. G.; Hepp, M.; Schunack, W. Histamine Analogues. XVI. Synthesis and Action of 5-Alkyl substituted Histamines and N^α-Methylhistamines. Eur. J. Med. Chem. Chim. Ther. 1978, 13, 229–234.

⁽⁴¹⁾ Black, J. W.; Duncan, W. A. M.; Durant, G. J.; Ganellin, C. R.; Parsons, M. E. Definition and Antagonism of Histamine H₂-Receptors. *Nature (London)* 1972, 236, 385-390.

⁽⁴²⁾ van Rossum, J. M. Cumulative Dose Response Curves. Arch. Int. Pharmacodyn. Ther. 1963, 143, 299-330.

⁽⁴³⁾ Bowsher, R. B.; Verburg, K. M.; Henry, D. P. Rat Histamine N-Methyltransferase. Quantification, Tissue Distribution, Purification and Immunologic Properties. J. Biol. Chem. 1983, 258, 12215-12251.

⁽⁴⁴⁾ Garbarg, M.; Dam Trung Tuong, M.; Gros, C.; Schwartz, J. C. Effects of Histamine H₃-Receptor Ligands on Various Biochemical Indices of Histaminergic Neuron Activity in Rat Brain. *Eur. J. Pharmacol.* 1989, 164, 1-11.

⁽⁴⁵⁾ Black, J. W.; Ganellin, C. R. Naming Substituted Histamines. Experientia 1974, 30, 111-113.

 ⁽⁴⁶⁾ Davies, E. K. CHEMX1990; developed and distributed by Chemical Design Ltd., Oxford, England.
(47) Parker, R. B.; Waud, D. R. Pharmacological Estimation of Drug-

⁽⁴⁷⁾ Parker, R. B.; Waud, D. R. Pharmacological Estimation of Drug-Receptor Dissociation Constants. Statistical Evaluation. II Competitive Antagonists. J. Pharmacol. Exp. Ther. 1971, 177, 13-24.

⁽⁴⁸⁾ Sachs, L. Angewandte Statistik; Springer Verlag: Berlin, 1984; p 77.